Keloids - Pipeline Review, H1 2020

Publication Month: Jun 2020 | No. of Pages: 64 Published By: Global Markets Direct
Single User License: US $ 2000
Corporate User License: US $ 6000

Keloids - Pipeline Review, H1 2020

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Keloids - Pipeline Review, H1 2020, provides an overview of the Keloids (Dermatology) pipeline landscape.

Keloids are a growth of extra scar tissue where the skin has healed after an injury. Symptoms include flesh-colored, red, or pink, lumpy (nodular) or ridged, irritated from friction such as rubbing on clothing and tender and itchy. Risk factors include age and family history. Treatment includes corticosteroid, radiation, surgical removal and silicone gel or patches.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Keloids - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Keloids (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Keloids (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Keloids and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 2, 4, 1 and 1 respectively.

Keloids (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Keloids (Dermatology).
- The pipeline guide reviews pipeline therapeutics for Keloids (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Keloids (Dermatology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Keloids (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Keloids (Dermatology)

Reasons to Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Keloids (Dermatology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Keloids (Dermatology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Keloids - Overview
Keloids - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Keloids - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Keloids - Companies Involved in Therapeutics Development
Allianz Pharmascience Ltd
FBM Therapeutics LLC
FirstString Research Inc
Lemonex Inc
Miragen Therapeutics Inc
Next Science Ltd
Phio Pharmaceuticals Corp
siRNAgen Therapeutics Corp
Sirnaomics Inc
Tumorend LLC
Yuhan Corp
Keloids - Drug Profiles
ALZ-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense RNAi Oligonucleotide to Inhibit Amphiregulin for Hypertrophied scar and Keloid - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CM-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug for Keloids - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FBM-5712 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Granexin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LEM-S401 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
remlarsen - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RXI-109 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
STP-705 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
YHC-1113 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Keloids - Dormant Projects
Keloids - Discontinued Products
Keloids - Product Development Milestones
Featured News & Press Releases
Jun 02, 2015: RXi Pharmaceuticals to Present at the 23rd World Congress of Dermatology
Apr 29, 2014: RXi Pharmaceuticals Announces Initiation of Phase 2a Keloid Study
Mar 05, 2014: RXi Pharmaceuticals Granted Key Patent Related to Self-Delivering Technology for the Treatment of Fibrotic Disorders
Dec 04, 2013: RXi Pharmaceuticals Announces mRNA Data of an Additional Cohort in the Second Phase 1 Multi-Dose Study with RXI-109, Extending the Dose Response Following Treatment in the Initial 2-week Period
Nov 18, 2013: RXi Pharmaceuticals and Ethicor Announce the Signing of a Distribution Agreement for RXI-109 in the European Union under the "Specials" Provision
Jun 06, 2013: RXi Pharmaceuticals Announces Positive Results In First Double Blind Study In Healthy Volunteers With RXI-109
Jan 30, 2013: RXi Pharma Completes Enrollment In Second Phase I Trial For RXI-109 Program
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Tables and Figures

List of Tables
Number of Products under Development for Keloids, H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Keloids - Pipeline by Allianz Pharmascience Ltd, H1 2020
Keloids - Pipeline by FBM Therapeutics LLC, H1 2020
Keloids - Pipeline by FirstString Research Inc, H1 2020
Keloids - Pipeline by Lemonex Inc, H1 2020
Keloids - Pipeline by Miragen Therapeutics Inc, H1 2020
Keloids - Pipeline by Next Science Ltd, H1 2020
Keloids - Pipeline by Phio Pharmaceuticals Corp, H1 2020
Keloids - Pipeline by siRNAgen Therapeutics Corp, H1 2020
Keloids - Pipeline by Sirnaomics Inc, H1 2020
Keloids - Pipeline by Tumorend LLC, H1 2020
Keloids - Pipeline by Yuhan Corp, H1 2020
Keloids - Dormant Projects, H1 2020
Keloids - Discontinued Products, H1 2020



Companies Mentioned
Allianz Pharmascience Ltd
FBM Therapeutics LLC
FirstString Research Inc
Lemonex Inc
Miragen Therapeutics Inc
Next Science Ltd
Phio Pharmaceuticals Corp
siRNAgen Therapeutics Corp
Sirnaomics Inc
Tumorend LLC
Yuhan Corp

Reason to Buy

  • Current and future of Pharma & Healthcare Market outlook in the developed and emerging markets
  • Highlights key business priorities in order to assist companies to realign their business strategies
  • The segment that is expected to dominate the Pharma & Healthcare Market
  • Regions that are expected to witness the fastest growth during the forecast period
  • Identify the latest developments, Pharma & Healthcare Market shares, and strategies employed by the major market players
  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the global Pharma & Healthcare Market
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets